Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) – Research analysts at Cormark decreased their Q3 2016 earnings per share estimates for Cipher Pharmaceuticals in a research report issued on Monday. Cormark analyst D. Novak now anticipates that the firm will earn ($0.10) per share for the quarter, down from their prior estimate of ($0.05). Cormark also issued estimates for Cipher Pharmaceuticals’ Q4 2016 earnings at ($0.06) EPS and FY2016 earnings at ($0.39) EPS.

A number of other research firms have also weighed in on CPHR. TD Securities reiterated a “buy” rating and set a $7.50 price objective on shares of Cipher Pharmaceuticals in a research note on Saturday, August 13th. GMP Securities reiterated a “hold” rating on shares of Cipher Pharmaceuticals in a research note on Saturday, August 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $6.85.

Shares of Cipher Pharmaceuticals (NASDAQ:CPHR) traded up 0.000% during midday trading on Wednesday, reaching $3.879. The company’s stock had a trading volume of 101 shares. Cipher Pharmaceuticals has a one year low of $3.55 and a one year high of $6.37. The stock’s 50 day moving average price is $4.03 and its 200 day moving average price is $5.09. The firm’s market cap is $101.61 million.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

5 Day Chart for NASDAQ:CPHR

Receive News & Stock Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.